– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near ‑ maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease ( COPD) patients produced rapid improvement in FEV 1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid